Introduction
Nephropathy is defined as partial loss of function of kidney associated with nephrotic syndrome, glomerulosclerosis, persistent albuminuria, declining glomerular filtration rate (GFR), elevated arterial blood pressure and fluid retention. 1, 2 The underlying pathogenesis of nephropathy involves downregulation of endothelial nitric oxide synthase (eNOS) and upregulation of inflammatory mediators, such as intracellular adhesion molecule-1, vascular cell adhesion molecule-1, von Willebrand factor, nuclear factor kappa-B and various growth factors like vascular endothelial growth factor, basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-β (TGF-β), fibronectin and inflammatory cytokines, which collectively affect the structure and function of the kidneys. [3] [4] [5] Further, downregulation of neuronal nitric oxide synthase has been noted in experimental diabetic nephropathy 6 in the kidneys of rats with glomerulosclerosis. 7, 8 In addition, numerous endogenous modulators, such as angiotensin II, 9 endothelin-I, 10 arginine vasopressin, 11 urotensin-II, 12 asymmetric dimethylarginine, 13 caveolin, 14 C-reactive protein, 15 leptin, 16 resistin 17 and Rho-kinase, 18 have been implicated in the pathogenesis of nephropathy. A correlation between diabetes and vascular endothelial dysfunction has been demonstrated. 19 Vascular endothelial dysfunction results in reduced activation of eNOS, reduced generation and bioavailability of nitric oxide (NO), and increased production of reactive oxygen species (ROS). [20] [21] [22] [23] The downregulation of eNOS in diabetes has been noted to accelerate diabetic nephropathy. 19 Although several factors mediate the development and progression of nephropathy, hyperglycaemia and associated comorbid conditions, such as atherosclerosis and hypertension, are considered to be independent risk factors and major determinants in the progression of nephropathy in patients with diabetes. Various experimental models are employed to induce nephropathy in order to identify the potential pharmacological targets for nephropathy. However, the literature for animal models of nephropathy is currently inadequate. This review focuses on various experimentally-developed animal models producing nephropathy. tubular necrosis and reduced GFR. The number of patients with end-stage renal failure requiring dialysis is increasing. Therefore, suitable animal models that exhibit progressive renal lesions are necessary to identify the mechanisms involved in human nephropathy and to develop potential drugs for the treatment of renal complications.
Diabetes-induced nephropathy Streptozotocin
(STZ, 2-deoxy-2-(3-methyl-3nitrosoureido)-D-glucopyranose) was discovered in a strain of the soil microbe Streptomyces achromogenes. It was classified as an alkylating agent in the nitrosourea class of anti-cancer drugs and was used to treat cancer of Islets of Langerhans in the pancreas. STZ is toxic to the insulinproducing beta cells of the Islets of Langerhans in the pancreas, and thus it is widely employed to induce experimental diabetes in animals. Administration of a single dose of STZ (40 mg/kg, 50 mg/kg, 55 mg/kg, 60 mg/kg and 65 mg/kg i.p. or i.v.) in rats results in hyperglycaemia within 72 hours. 3, 18, [24] [25] [26] [27] Nephropathy was noted in rats between 4-8 weeks after the administration of STZ (50 mg/kg, 55 mg/kg, 60 mg/kg i.p., once) as assessed in terms of significant increase in proteinuria, serum creatinine, blood urea nitrogen (BUN), extracellular matrix deposition and thickening of glomerular basement membrane. 18, 25, 26 STZ damages the DNA of the pancreatic-β cells and triggers multiple pathways, including activation of protein kinase-C, poly (ADP-ribose) polymerase and NAD(P)H oxidase, with consequent generation of ROS and advanced glycation end products resulting in renal damage and nephropathy. 27, 28 The experimental evidence suggests that STZ-induced diabetes downregulates the expression and activity of eNOS and decreases the bioavailability of NO, which aggravates nephropathy. 3 It has been noted that administration of STZ (35 mg/kg i.p., once) in rats with resection of half of one kidney and total removal of the other produced macroalbuminuria in 80 days, with markedly increased serum creatinine and triglycerides with glomerular and tubular lesions. 29 STZ administration (125 mg/kg/day i.p., for two days) in mice produced nephropathy, characterised by accumulation of macrophages, increase in proteinuria, glomerulosclerosis and tubulointerstitial fibrosis. 30 The accumulated macrophages secrete a number of cytokines including interleukin (IL)-1, platelet derived growth factor, fibroblast growth factor-2 and TGF-β, which are capable of inducing profibrotic responses in kidney cells including myofibroblast proliferation, extracellular matrix production and tubulointerstitial fibrosis. The STZ-induced diabetic nephropathy model is widely used in experimental studies and induces diabetic nephropathy within 4-6 weeks of the single dose injection of STZ. The mechanisms involved in STZ-induced diabetic nephropathy are shown in figure 1.
Genetic models are an essential experimental tool for investigating the molecular mechanisms and genetic susceptibility in the development of diabetic nephropathy. The Goto-Kakisaki (GK) rat is a genetic non-obese model of type 2 diabetes mellitus. The progressive hyperglycaemia was noted in GK rats during the experimental period started from the age of eight months to 24 months. It has been noted that GK rats at the age of 24 months developed nephropathy as characterised by significant increase in serum creatinine, BUN and morphological changes in kidneys, such as glomerulosclerosis and tubulointerstitial fibrosis. The observed renal changes of GK rats are noted to be similar to those of progressive human diabetic nephropathy. 31, 32 The CD1 mouse model for diabetic nephropathy has been noted to develop end-stage renal disease associated with prominent tubulointerstitial fibrosis and glomerulosclerosis within six months after a single injection of STZ. These mice developed nephropathy as measured in terms of increase in serum creatinine and proteinuria. Further, morphological changes in kidneys, such as development of mesangial matrix expansion and glomerular hypertrophy, were noted in CD1 mice. 33 Ciclosporin A-induced nephropathy Ciclosporin A, an inhibitor of calcineurin, has been employed as an immunosuppressant to treat autoimmune diseases. 34 Its clinical use is limited due to the development of nephropathy. 35 Ciclosporin A-induced nephropathy involves overexpression of IL-6, TGF-β and activation of NAD(P)H oxidase in endothelial cells, which damage the integrity of renal endothelium. It has been noted that administration of ciclosporin A (7.5 mg/kg/day and 15 mg/kg/day s.c.) for 28 days in rats developed nephropathy characterised by significant increase in serum creatinine, BUN and decrease in GFR with morphological changes such as tubular necrosis and renal endothelial dysfunction. 4, 36 In addition, a recent study showed that administration of ciclosporin A (20 mg/kg/day by gastric gavage) for 28 days developed glomerulosclerosis, tubulointerstitial fibrosis and proteinuria, which result in nephropathy. 37 Administration of ciclosporin A (25 mg/kg/day i.p.) for five weeks developed nephropathy in mice by increasing serum level of IL-6 and activating NAD(P)H oxidase. 38 Ciclosporin A-induced nephropathy model helps to understand the pathological mechanism involved in progressive glomerulosclerosis, tubulointerstitial fibrosis and tubular necrosis.
Anthracycline-induced nephropathy
Adriamycin (doxorubicin) is classified as an anthracycline class of antibiotic and it is an effective antitumour drug used to treat cancer of various organs such as bladder, breast, stomach and thyroid. However, the clinical use of adriamycin is restricted because of its clinical toxicity, such as the development of cardiomyopathy and nephropathy. 39, 40 Nephropathy was noted after administration of adriamycin (2 mg/kg i.v., twice at 20-day intervals) for 20 weeks in rats, as assessed in terms of significant increase in proteinuria, serum creatinine and BUN, and progression of glomerulosclerosis. 41 A single dose of adriamycin (20 mg/kg i.v.) induced severe nephropathy in mice with marked proteinuria, glomerulosclerosis and tubulointerstitial fibro-sis, involving upregulation of cytokines and growth factors. 40 Hyperlipidaemia can aggravate the primary renal disease in experimental animals. 42 Administration of adriamycin (1 mg/kg/day i.v., once a week) for 12 weeks in rats showed significant increase in serum level of low density lipoprotein and very low density lipoprotein, resulting in renal damage. 43 The hyperlipidaemia-mediated renal damage may involve vascular endothelial dysfunction and atherosclerosis of glomerular apparatus. Development of hyperlipidaemia, glomerulosclerosis and tubulointerstitial fibrosis is considered to be a major event in adriamycininduced nephropathy. 43 Daunomycin is another anthracycline antibiotic and is used to treat acute leukaemia. It has been noted that administration of daunomycin (12 mg/kg i.v., once) in rats induced nephropathy within four weeks with proteinuria, and increased serum creatinine and BUN. 44 Again, a single dose of daunomycin (20 mg/kg i.v.) induced severe nephropathy in rats and mice with glomerulosclerosis and mesangial matrix expansion. 45, 46 Glomerulosclerosis is considered to be an important process involved in daunomycin-induced nephropathy.
Electrolyte nephropathy
Electrolyte disturbances occur due to abnormalities in the levels of sodium (Na + ), potassium (K + ) and magnesium (Mg 2+ ). Electrolyte nephropathy is characterised by dysfunction of individual compartments of the nephron and is mainly caused by K + and Mg 2+ deficiency. Deficiency of K + in the ascending loops of Henle causes marked changes in acid status. Mg 2+ deficiency causes dysfunction in the renal tissue with deposition of Ca 2+ salts and impairment of K + and Na + transport into the renal cells. Rats receiving a diet containing disodium hydrogen phosphate (Na 2 HPO 4 .12H 2 O), which is deficient of K + and Mg 2+ , for 12 days developed electrolyte nephropathy. 47 During the period of this diet administration, rats had received 1% sodium chloride solution instead of water and in parallel hydrocortisone acetate (1.5 mg/100 g i.m., once daily), which developed electrolyte nephropathy and consequently produced morphological changes in kidneys such as glomerulosclerosis, glomerulonephritis and tubular necrosis. 47
Ethylene glycol-induced nephropathy
Ethylene glycol is an odourless and colourless liquid with a sweet taste and it is commonly used as an antifreeze agent in automobile cooling systems. Administration of ethylene glycol (50-400 mg/kg/day p.o.) for 12 months in diet developed nephropathy, as assessed in terms of development of glomerulosclerosis, extracellular matrix deposition and tubulointerstitial fibrosis. Ethylene glycol is metabolised into oxalic acid, which gets precipitated as calcium oxalate crystals in the kidneys that cause generation of ROS and consequently degeneration of renal tubule epithelium. 48 Glomerulosclerosis and tubulointerstitial fibrosis are the major events involved in ethylene glycolinduced nephropathy.
Aminoglycoside-induced nephropathy
Gentamicin, an aminoglycoside antibiotic, is used in the treatment of gram negative bacterial infections. However, nephrotoxicity is a major side effect of gentamicin that restricts its clinical application. 49 Nephropathy developed after administration of gentamicin (80 mg/kg, i.p.) for eight days in rats with proteinuria, increased serum creatinine and BUN, increased urinary loss of sodium and potassium, and glomerulosclerosis associated with excessive generation of ROS. 50 Administration of gentamicin at a higher dose (100 mg/kg, s.c.) for five days in rats induced nephropathy characterised by significant decrease in creatinine clearance with tubular necrosis. 51 The gentamicin-induced nephropathy model helps in understanding the mechanism involved in acute renal failure. Excessive ROS formation is responsible for the development of glomerulosclerosis, tubular necrosis and is implicated in gentamicin-induced nephropathy.
Puromycin is another aminoglycoside class of antibiotic, which causes excessive formation of ROS that damages the kidney. 52 Administration of puromycin (50, 40, 40 and 25 mg/kg s.c., in 0, 2 nd , 4 th and 6 th week, respectively) produced nephropathy in rats after six weeks. 52
Cadmium-induced nephropathy
Cadmium is a soft bluish-white metal and is used largely in metal coatings, plastics and alloy batteries. Chronic environmental exposure of cadmium is nephrotoxic. 53 It has been noted that administration of cadmium (0.18 mg/kg i.p., three times a week) for three months in rats led to hypertension followed by thickening of glomerular basement membrane, tubulointerstitial fibrosis and reduced GFR. 54 Administration of cadmium (1 ml of 1 mM, three times/week i.p.) for five, 20 and 40 weeks caused perturbation of kidney proximal tubular epithelial cells and mitochondrial dysfunction in renal cortical cells. 55 Tubulointerstitial fibrosis, elevated arterial blood pressure and fluid retention are the primary events implicated in cadmium-induced nephropathy.
Carbon tetrachloride-induced nephropathy
Carbon tetrachloride (CCl 4 ) is a colourless, volatile and nonflammable liquid and is known to cause hepatotoxicity and nephrotoxicity. 56 In the general population, the average daily intake of CCl 4 is low, but exposure to CCl 4 by ingestion, inhalation or skin absorption distributes it throughout the body with highest concentrations in liver and kidney. The metabolic transformation of CCl 4 results in the generation of free radicals, resulting in renal cell injury and kidney damage. Administration of CCl 4 (0.5 ml/kg s.c., three times a week) for seven weeks in rats induced prominent changes in the morphology of the kidney, including tubulointerstitial fibrosis and vascular congestion. 57 and cosmetics. It has anti-microbial, anti-tumour and immunomodulator properties. Administration of germanium (5.16 g/day) in the diet for 20 weeks induced nephropathy in rats with proteinuria, tubulointerstitial fibrosis and glomerular hypertension. Increased expression of collagen and TGF-β is implicated in GeO 2 -induced nephropathy. 58
Mercury chloride-induced nephropathy
Mercuric chloride (HgCl 2 ) is a white crystalline solid reagent known to cause renal proximal tubular damage. Administration of HgCl 2 (1 mg/ kg s.c.) on days 0, 2, 4, 7, 9 and 11 produced nephropathy on day 7 with negligible proteinuria, but enhanced sodium retention and by day 14 with increased proteinuria and greatest sodium retention. Markedly increased serum creatinine with tubular necrosis was noted on day 21 of administration. 59
Cisplatin-induced nephropathy
Cisplatin is used to treat various types of cancers, including sarcomas and carcinomas. Rats administered cisplatin (7 mg/kg i.v., once) developed nephropathy in six to seven days with increased serum creatinine and BUN, and reduced serum albumin levels. 60, 61 The mechanism involved in cisplatin-induced nephropathy includes inhibition of protein synthesis, DNA damage, mitochondrial injury and apoptotic cell death in renal tubules. Cisplatin reduces the bioavailability of NO, which upregulates monocyte chemoattractant protein-1, connective tissue growth factors and tumor necrosis factor-α, which play a central role in renal damage. Moreover, cisplatin generates excessive ROS, which activate mitogen activated protein kinase causing renal injury and inflammation. 60, 61 Cisplatin-induced nephropathy model also helps to understand the mechanisms involved in the induction of acute renal failure.
Vomitoxin-induced nephropathy
Vomitoxin, also known as deoxynivalenol, is obtained from the fungus Fusarium graminearum, present on grains such as wheat, barley and maize. Immunoglobulin A (IgA) nephropathy is the most common form of primary glomerulonephritis. High serum IgA concentration is considered to be an important contributory factor in IgA nephropathy. IgA binds to its receptors on mesangial cells and thereby induces the proliferation of mesangial cells and cytokine production to cause glomerular damage. 62 Children and young adults are mainly affected by this disease and often develop end-stage renal disease. Administration of deoxynivalenol (25 mg/kg oral gavage, once) in mice produced nephropathy characterised by an increase in serum IgA levels, which in turn upregulates and activates inflammatory mediators like IL-6 and mitogen activated protein kinase. 63
Maleic acid-induced nephropathy
Administration of maleic acid (100 mg/kg i.v., once) in rats induced nephropathy within 24 hours. 64 Maleic acid induces a rapid, reversible and complex dysfunction of the renal tubule, which is associated with glycosuria, aminoaciduria, bicarbonaturia and phosphaturia. In addition, maleic acid induces other transport abnormalities, including interference with Na + -dependent co-transport and reabsorption. 64, 65 
Conclusion
During the past few decades, the use of animal models has provided new insights into understanding the complex pathogenesis of nephropathy. The morbidity and mortality due to nephropathy are continuously increasing worldwide and the therapeutic agents currently available are limited. Important pathogenic mechanisms still remain active and unmodified by present therapeutic strategies. Identification of signalling culprits involved in nephropathy using various animal models may provide the lead in discovering novel therapeutic agents.
